首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1425109

新生兒篩檢市場 – 2024-2029 年預測

Newborn Screening Market - Forecasts from 2024 to 2029

出版日期: 2024年01月25日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年新生兒篩檢產業的市場規模為1,026,817,000美元，預計在預測期內複合年成長率為8.31%。

新生兒篩檢用於識別可能影響兒童長期健康的各種狀況。一系列測試主要涉及篩檢技術，以便及時發現、健康管理和早期診斷，防止整體殘疾。這些測試可檢測兒童的發育、遺傳和代謝疾病。新生兒篩檢是在出院前從嬰兒腳跟抽取幾滴血液檢查是否有嚴重的先天性心臟疾病。

新生兒篩檢市場的促進因素

由於政府舉措的不斷增加和篩檢技術的各種發展，新生兒篩檢市場預計將成長。高出生率和新生兒疾病盛行率增加是影響經濟成長的其他一些主要因素。此外，印度等新興市場的遺傳疾病篩檢為主要企業提供了主要的市場成長機會。出生率的上升和可支配收入的增加也推動了新生兒篩檢市場的發展

乾血斑檢測預計將佔據最大的市場佔有率

預計乾血檢測將在預測期內主導新生兒篩檢產業。這些測試用於先天性代謝紊亂的檢測已有 50 多年的歷史。乾血測試是有利的，因為它們很容易用腳後跟棒或手指取樣，需要的量極少，並且易於運輸。白血病、淋巴瘤和自閉症可以透過乾血測試來檢測。乾血檢測的優點是可以採集小樣本且易於運輸。因此，新生兒疾病數量的增加正在推動新生兒篩檢市場的發展。

快速發展的新藥管道

新藥和生技藥品的研發管線正在迅速擴大。例如，Zolgensma 是第一個用於新生兒篩檢疾病的基因治療藥物，在 Spinraza 獲得 FDA核准後不久就上市了。 SMA因此被涵蓋國家統計局。由於這些藥物非常稀有，因此藥物變得非常昂貴的可能性仍然是一個威脅。例如，Zolgensma 每劑成本約為 220 萬美元。此外，政府、家庭和醫療保健專業人員的責任對於制定各種新生兒篩檢計畫至關重要。此外，主要的新生兒篩檢市場領導正在關注新藥的產品創新。

政府加大力度

政府不斷採取的舉措正在推動新生兒篩檢市場的成長。例如，世界衛生組織（WHO）建議在全球範圍內實施新生兒篩檢計劃，以保護兒童的健康。美國衛生與公眾服務部新生兒和兒童遺傳性疾病部長諮詢委員會 (PEACH) 和眾多倡導團體已製定了多項政策和指南。資金籌措的增加和需要篩檢的各種疾病是推動市場成長的主要因素。

在北美，新生兒篩檢市場預計將穩定成長。

由於許多國家先天性疾病盛行率的增加和檢測力度的加強，預計北美的新生兒篩檢市場在預測期內將會成長。所有北美國家都致力於新生兒篩檢計劃。篩檢標準由美國醫學遺傳學學院 (ACMG) 透過廣泛研究提供，該學院由美國衛生與公眾服務部監督。此外，為了提高家長的認知，美國衛生署發布了免費資料並創建了一個網站。

主要市場公司的成長策略

新生兒篩檢公司正專注於發展其生產設施並進行各種併購活動，以加強其在新生兒篩檢市場的地位。例如，2022 年 8 月，Perkin Elmer 將其應用、食品和企業業務出售給 New Mountain Capital, LLC。賠償總額為24.5億美元。新生兒篩檢產業的公司也將先進技術和創新融入各種產品中，以滿足消費者的需求。此外，公共和私人機構之間也開展新生兒篩檢合作。

新生兒篩檢產品

Panthera PuncherTM 9：下一代乾式樣品沖壓工具 Panthera PuncherTM 9 由 PerkinElmer 製造。 PerkinElmer 作為新生兒篩檢領域的先驅，選擇了必要的技術選項和材料來確保沖壓完美。
EONISTM Q384：EONISTM Q 384 孔版儀器採用易於理解且獨特的工作流程創建，使 qPCR 培訓和部署變得輕鬆。
VARIANT NBS新生兒篩檢系統：VARIANTnbs 已成為新生兒篩檢鐮狀貧血等血紅蛋白異常的事實上的標準。它具有全自動分析和最先進的結果報告，可實現最佳效果。

Newborn screening is utilized to identify various conditions that affect the child's long-term health. A series of tests are involved in the screening technology mainly timely detection, health management, and early diagnosis to prevent overall disability. These tests detect developmental, genetic, and metabolic disorders in children. Newborn screening is performed by using a few drops of blood from the newborn's heel and are tested for critical congenital heart defects before discharge from hospitals.

Driving factors for the newborn screening market

The newborn screening market is anticipated to grow owing to rising government initiatives and various developments in screening technology. High birth rates and an increase in the prevalence of neonatal disease are some of the other key factors influencing the growth. Furthermore, the screening of genetic disorders in developing nations like India provides significant newborn screening market growth opportunities for key players. An increase in birth rate and disposable income is also fueling the newborn screening market

Dried blood spot tests are anticipated to hold the maximum market share

Dried blood tests are predicted to dominate the newborn screening industry during the forecast period. These tests have been used for congenital metabolic diseases for over 50 years. Dried blood tests are advantageous due to ease of sample attainment by finger of heel stick, include minimal volume requirements, and are easier to transport. Leukemia, lymphomas, and autism can be detected using the dried blood test. It offers the advantage of collecting small sample volumes which are easier to transport. Therefore, the rising number of diseases in newborns is fueling the newborn screening market.

Rapidly developing pipeline of novel medicines

The pipeline of novel medicines and biologics is quickly expanding. For instance, the first gene therapy for newborn screening disorder, Zolgensma was made accessible shortly after Spinraza was approved by the FDA. This resulted in the inclusion of SMA in the NBS. Since these medicines are very uncommon, the possibility of the medications being very expensive is still a threat. For instance, Zolgensma costs around $2.2 million for a one-dose therapy. Additionally, for the creation of various newborn screening programs, the responsibilities of government, families, and healthcare professionals have been crucial. Furthermore, major newborn screening market leaders are focusing on product innovation for novel medicines.

Increasing government initiatives

Growth in government initiatives is fueling the newborn screening market growth. For instance, the World Health Organization recommended newborn screening programs to safeguard children's health globally. Numerous policies and guidelines were taken by the U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children, UK (PEACH), and many advocacy groups. Increasing funding and various conditions requiring screening are the key factors contributing to the growth of the market.

In North America, it is projected that the newborn screening market will grow steadily.

The newborn screening market is anticipated to grow in North America during the projected period due to the increasing prevalence of congenital disorders and enforced testing in many nations. All the North American nations diligently follow the newborn screening programs. Through extensive research by the American College of Medical Genetics (ACMG) which is done under the supervision of the U.S. Department of Health and Human Services, the screening conditions are provided. Additionally, to raise awareness among parents the health departments of the United States have released free data and created websites.

Growth strategies by major market players

The newborn screening companies are focusing on growing their manufacturing facilities and are engaging in various merger and acquisition activities to strengthen their newborn screening market position. For instance, in August 2022, Perkin Elmer sold its Applied, Food, and Enterprise business to New Mountain Capital, LLC. With a total compensation of $2.45 billion. The newborn screening industry players have also been involved in various product innovations owing to the incorporation of advanced technology and meeting consumer requirements. Additionally, collaborations are being done between public and private organizations for newborn screening.

Newborn Screening Products

Panthera PuncherTM 9, The next generation Panthera PuncherTM 9 dry sample punching tool is manufactured by PerkinElmer. PerkinElmer, a pioneer in newborn screening, has chosen the technological options and materials required to guarantee a new benchmark for punching perfection.
EONISTM Q384, The EONISTM Q 384-well version instrument was created with a straightforward and distinctive workflow, making qPCR training and deployment simple to carry out. The EONISTM Q promises a turnaround time of under two hours and doesn't require a clean room because of the streamlined procedure.
VARIANT NBS Newborn Screening System, The VARIANTnbs has become the de facto standard for automated newborn screening for hemoglobin abnormalities such as sickle cell anemia. For optimal effectiveness, it has completely automated analysis and cutting-edge result reporting.

Market Key Developments

In July 2023, At the AMTZ Campus in Vishakhapatnam, India, a Centre of Excellence (CoE) with cutting-edge R&D and manufacturing capabilities was established by Triviton Healthcare.
In June 2023, To educate the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening for communication disorders in children, the Department of Health and Family Welfare and the All India Institute of Speech and Hearing (AIISH), based in Mysuru, have partnered to expand the Newborn Screening Programme (NBS).
In June 2022, according to a novel program announced by Rady Children's Institute for Genomic Medicine BeginNGSTM is being used to screen newborns for roughly 400 genetic diseases for which there are known treatments using rapid whole genome sequencing.

Segmentation:

By Technology

Immune Assays & Enzymatic Assays
Tandem Mass Spectrometry
Molecular Assays
Hearing Screening Technologies
Others

By Test

Dry Blood Spot Tests
Hearing Screening Tests
CCHD Screening Tests

By End-User

Clinical Laboratories
Hospitals

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. NEWBORN SCREENING MARKET, BY TECHNOLOGY

5.1. Introduction
5.2. Immune Assays & Enzymatic Assays
5.3. Tandem Mass Spectrometry
5.4. Molecular Assays
5.5. Hearing Screening Technologies
5.6. Others

6. NEWBORN SCREENING MARKET, BY TEST

6.1. Introduction
6.2. Dry Blood Spot Tests
6.3. Hearing Screening Tests
6.4. CCHD Screening Tests

7. NEWBORN SCREENING MARKET, BY END-USER

7.1. Introduction
7.2. Clinical Laboratories
7.3. Hospitals

8. NEWBORN SCREENING MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others